EAM Investors’s Viking Therapeutics VKTX Stock Holding History

EAM Investors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-73,063	Closed	-$5.99M	–	350
2024 Q1	$5.99M	Sell	73,063 -95,974	-57%	-$4.27M	0.93%	3
2023 Q4	$3.15M	Buy	+169,037	New	+$2.21M	0.56%	105
2023 Q2	–	Sell	-339,659	Closed	-$5.66M	–	375
2023 Q1	$5.66M	Sell	339,659 -155,281	-31%	-$1.6M	1.11%	3
2022 Q4	$4.65M	Buy	+494,940	New	+$2.21M	0.96%	4
2019 Q1	–	Sell	-200,047	Closed	-$1.53M	–	323
2018 Q4	$1.53M	Sell	200,047 -78,665	-28%	-$941K	0.42%	105
2018 Q3	$4.86M	Sell	278,712 -90,370	-24%	-$1.08M	0.72%	12
2018 Q2	$3.5M	Buy	369,082 +54,081	+17%	+$360K	0.55%	46
2018 Q1	$1.38M	Sell	315,001 -63,519	-17%	-$351K	0.23%	166
2017 Q4	$1.54M	Buy	+378,520	New	+$1.1M	0.28%	165

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

EAM Investors's VKTX Position: Q2 2024 in Review

EAM Investors sold out of Viking Therapeutics (VKTX) in Q2 2024, closing a stake of 73,063 shares — an estimated $5.99M sold.

EAM Investors first reported a position in VKTX in Q4 2017 and held it in 9 quarters. The position peaked at $5.99M in Q1 2024. 387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

EAM Investors reported no remaining Viking Therapeutics position as of Q2 2024 after selling out during the quarter.
EAM Investors sold 73,063 Viking Therapeutics shares in Q2 2024, an estimated $5.99M.
EAM Investors first reported a position in Viking Therapeutics in Q4 2017 and held it in 9 quarters.
EAM Investors's Viking Therapeutics position peaked at $5.99M in Q1 2024.
387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on EAM Investors's 13F filing for Q2 2024, filed 12 Aug 2024.